NCT00652574View on ClinicalTrials.gov

Dasatinib in Resectable Malignant Pleural Mesothelioma

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

March 12, 2008

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG

Dasatinib

70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

United States Department of Defense

FED

lead

M.D. Anderson Cancer Center

OTHER

NCT00652574 - Dasatinib in Resectable Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter